Market Overview

Depomed to Present at Four Investor Events in December


NEWARK, Calif., Nov. 24, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the following investor events during the month of December.

Piper Jaffray 27th Annual Healthcare Conference
Date: Wednesday, December 2, 2015
Time: 2:30 p.m. EST
Location: New York, New York

Oppenheimer 26th Annual Healthcare Conference
Date: Tuesday, December 8, 2015
Time: 8:00 a.m. EST
Location: New York, New York

RBC Capital Markets' Denver Healthcare Investor Day
Date: Thursday, December 10, 2015
Location: Denver, Colorado

UBS Annual West Coast Investor Trip
Date: Tuesday, December 15, 2015
Location: Depomed Offices, Newark, California

The Piper Jaffray and Oppenheimer presentations will be webcast and can be accessed via the Investor Relations page of the Depomed website at  A recording of the webcasts will be archived for 30 days on the company's website.

About Depomed 

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Our NUCYNTA® franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise, NUCYNTA ER and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at

NUCYNTA®, Gralise® CAMBIA®, Zipsor®, Lazanda® and Acuform® are registered trademarks of Depomed, Inc.


Depomed, Inc.  
Christopher Keenan


To view the original version on PR Newswire, visit:

SOURCE Depomed, Inc.

View Comments and Join the Discussion!